Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Depreciation & Amortization (CF) (2019 - 2025)

Eton Pharmaceuticals' Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $1.0 million for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 262.95% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $3.4 million, up 203.05%, while the annual FY2024 figure was $1.1 million, 27.19% up from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $1.0 million at Eton Pharmaceuticals, roughly flat from $1.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.2 million in Q2 2022 and bottomed at $85000.0 in Q2 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $234000.0 (2024), against an average of $384736.8.
  • The largest annual shift saw Depreciation & Amortization (CF) skyrocketed 1277.65% in 2022 before it crashed 85.31% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $137000.0 in 2021, then skyrocketed by 83.94% to $252000.0 in 2022, then rose by 28.97% to $325000.0 in 2023, then rose by 9.23% to $355000.0 in 2024, then soared by 184.23% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Depreciation & Amortization (CF) are $1.0 million (Q3 2025), $1.0 million (Q2 2025), and $1.0 million (Q1 2025).